U.S. stock market midday update: AEON Biopharma's debt restructuring raises market concerns, stock price plummets 9.71%

U.S. Stock Market Midday Update AEON Biopharma fell 9.71%. Based on recent news, On December 15, AEON Biopharma announced a $15 million convertible note and accrued interest exchange agreement with Bear Pharmaceutical. This agreement will eliminate over 90% of AEON's outstanding debt and reshape its capital structure. Following this announcement, market concerns about its financial condition intensified, leading to a decline in stock price. On December 15, AEON Biopharma signed a final agreement with Bear Pharmaceutical to convert the $15 million convertible note and accrued interest into new equity and issue cash-exercise warrants for 8 million shares of common stock. If exercised, AEON will gain over $8 million in potential additional cash benefits. Although this move aims to strengthen long-term strategic alignment, the market expressed concerns about its short-term financial impact, further pressuring the stock price. On December 15, AEON Biopharma announced that the exchange agreement with Bear Pharmaceutical would significantly reduce its debt burden and improve its capital structure. However, investors remain skeptical about its future profitability and cash flow sustainability, leading to pressure on the stock price. The biopharmaceutical industry has been volatile recently, and investors should exercise caution. Top Stocks by Industry Trading Volume AbbVie rose 0.87%. Based on recent key news: On December 17, market analysis showed that although AbbVie was rated "Moderate Buy," top analysts believe there are five stocks that are more worthy of investment. This news may affect investor confidence, leading to stock price fluctuations. On December 16, analyst reports indicated that AbbVie was not included in the top recommended stock list, despite its "Moderate Buy" rating, which may lead investors to reassess their portfolios. On December 15, market observations noted that AbbVie was not among the five stocks recommended by analysts, despite its "Moderate Buy" rating, which may affect market expectations for its future performance. The pharmaceutical industry has shown stable performance recently, with attention on policy changes. Gilead Sciences rose 1.94%. Based on recent key news: On December 15, Gilead Sciences announced that its experimental HIV treatment met its primary endpoint in late-stage trials. This news boosted market confidence in the company's strategic expansion in the HIV field, driving the stock price up. On December 16, Gilead Sciences' Chief Financial Officer Andrew D. Dickinson and Chief Commercial Officer Johanna Mercier reported the sale of the company's common stock. This move may raise market attention on insider trading, affecting stock price fluctuations. On December 17, Gilead Sciences' annualized return over the past 20 years exceeded the market average, reaching 11.48%. This long-term performance may enhance investor confidence in the company's stock, supporting the stock price increase. Competition in the HIV treatment field is intensifying, and attention should be paid to policy changes Amgen fell 0.04%. Based on recent news: On December 18, HSBC raised Amgen's target price from $381 to $425 and maintained a buy rating. This move is part of the bank's outlook for the pharmaceutical industry in 2026, boosting market confidence in Amgen and driving stock price fluctuations. On December 15, MarketBeat noted that although Amgen received a moderate buy rating, top analysts believe there are five stocks that are more worthy of investment. This information may affect investors' interest in Amgen, leading to slight stock price fluctuations. The outlook for the pharmaceutical industry is positive, with significant capital inflows. Stocks ranked among the top in industry market capitalization Forte Pharma fell 0.83%. No significant news recently; trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. no_news